Light Therapy for University Students
15 giugno 2026 aggiornato da: Birna Baldursdottir, Reykjavik University
Effects of Light Therapy on Well-being of University Students: A Pilot Study
The effects of light therapy on well-being among university students was investigated.
A three-week intervention study examined whether the use of light glasses improved sleep quality and concentration and reduced symptoms of depression and anxiety among university students.
First, a questionnaire was administered to about 130 students to screen for sleep problems.
Based on the responses, those with the most sleep problems were invited to participate in the intervention study, which resulted in 39 participants in total.
Although studies of light therapy for sleep problems and depression among patients have yielded positive results, the use of light has not been studied much among healthy individuals.
The intervention study used glasses that project light in two intensities and participants were randomized into two groups with different intensities of light.
The aim of the study was to: a) compare the effects of different light intensities on sleep and concentration and b) investigate whether light therapy influences symptoms of depression and anxiety among university students.
The study is expected to increase knowledge of light therapy among healthy individuals, and if the treatment proves successful, it is an easy and inexpensive way to increase well-being among university students.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
39
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Reykjavik, Islanda, 102
- Department of Psychology, Reykjavík University
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Descrizione
Inclusion Criteria:
- Being psychology students at Reykjavik University, Iceland
- Able to understand, read and write Icelandic
- At screening assessment prior to the intervention, demonstrating a score of three or above on any of the six items of the BIS scale, thereby including students who showed even mild symptoms of sleep problems
Exclusion Criteria:
- Not being psychology students at Reykjavik University, Iceland
- Not able to understand, read and write Icelandic
- Demonstrating a score below three on all of the six items of the BIS scale
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Blue Light Therapy
Exposure of experimental circadian-effective blue light (BL) by glasses for 30 minutes each morning during the 3-week intervention
|
The circadian-effective light glasses used by the experimental group (BL) emitted narrowband (peak lambda = 470 nm) blue light with an irradiance of 250 μW/cm2 (120 lux). The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light. Brand: AYO glasses. |
|
Comparatore attivo: Dim Light Therapy
Exposure of experimental comparison cirdadian-ineffective dim light (DL) by glasses for 30 minutes each morning during the 3-week intervention
|
The circadian-ineffective sham glasses (DL) emitted blue light with an irradiance of 2.5 μW/cm2 (1.16 lux). The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light. Brand: AYO glasses. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The Bergen Insomnia Scale (BIS)
Lasso di tempo: BIS was used to screen for sleep-related problems, prior to the intervention, at baseline (day 1), at the middle of intervention (FU1, day 11) and at the of intervention (FU2, day 21).
|
The Bergen Insomnia Scale (BIS) is a short scale on sleep habits consisting of six items pertaining to sleep onset, maintenance, early morning wakening, restorative sleep, daytime functioning, and sleep satisfaction.
Responses indicate how often sleep problems, according to the six items, are experienced during the last month on an 8-point scale (0-7 days per week) with a range between 0 and 42, where a higher score suggests more sleep problems.
|
BIS was used to screen for sleep-related problems, prior to the intervention, at baseline (day 1), at the middle of intervention (FU1, day 11) and at the of intervention (FU2, day 21).
|
|
The Pittsburgh Sleep Quality Index (PSQI)
Lasso di tempo: PSQI was administered at baseline (day 1), FU1 (day 11), and FU2 (day 21).
|
The Pittsburgh Sleep Quality Index (PSQI) consists of 19 self-rated items about sleep habits during the last month.
The questions are categorised into seven components, rated from 0 to 3, evaluating sleep duration, quality, and latency as well as habitual sleep efficiency, sleep disturbances, usage of sleep medication, and daytime dysfunction.
A global PSQI score, ranging from 0 to 21, is calculated by summarising the seven components' scores, where a higher global score indicates worse sleep quality and a score above five suggests poor sleep quality.
|
PSQI was administered at baseline (day 1), FU1 (day 11), and FU2 (day 21).
|
|
Objective sleep measure by actigraphy: Total time in bed
Lasso di tempo: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep.
Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software.
Parameter measured: Total time in bed, measured as minutes.
|
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
|
Objective sleep measure by actigraphy: Total sleep time
Lasso di tempo: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep.
Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software.
Parameter measured: Total sleep time, measured as minutes.
|
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
|
Objective sleep measure by actigraphy: Sleep latency
Lasso di tempo: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep.
Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software.
Parameter measured: Sleep latency, measured as minutes.
|
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
|
Objective sleep measure by actigraphy: Wake after sleep onset
Lasso di tempo: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep.
Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software.
Parameter measured: Wake after sleep onset, measured as minutes.
|
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
|
Objective sleep measure by actigraphy: Number of awakenings
Lasso di tempo: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep.
Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software.
Parameter measured: Number of awakenings, measured as number of awakenings per sleep period.
|
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
|
Objective sleep measure by actigraphy: Sleep fragmentation index
Lasso di tempo: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep.
Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software.
Parameter measured: Sleep fragmentation index, measured as percentage.
|
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
|
Objective sleep measure by actigraphy: Sleep movement index
Lasso di tempo: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep.
Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software.
Parameter measured: Sleep movement index, measured as events per hour.
|
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
|
Objective sleep measure by actigraphy: Sleep efficiency
Lasso di tempo: Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
Wrist-worn actigraphy devices (model GT3X+ ActiSleep) were used to objectively measure sleep.
Sleep parameters were calculated using the Cole-Kripke sleep algorithm in the ActiLife 6 data analysis software.
Parameter measured: Sleep efficiency, measured as percentage.
|
Participants were asked to wear the devices on their non-dominant arm for four consecutive days, both at baseline (day 1-4) and at FU2 (day 18-21).
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The Center for Epidemiological Studies Depression Scale (CES-D)
Lasso di tempo: CES-D was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
|
The Center for Epidemiological Studies Depression Scale (CES-D) is a 20 item self-report instrument, designed to measure common symptoms of depression that have occurred over the past week such as poor appetite, hopelessness, pessimism, and fatigue.
Response options range from 0 to 3 for each item.
Scores range from 0 to 60, with high scores indicating greater depressive symptoms.
|
CES-D was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
|
|
General Anxiety Disorder (GAD-7)
Lasso di tempo: GAD-7 was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
|
General Anxiety Disorder (GAD-7) is a shorter version of the original GAD-13 item scale designed to measure anxiety.
Each of the seven questions is rated on a 4-point Likert scale based on symptom frequency.
The total score is calculated by summing the scores for all seven items, thus scores range from 0 to 21, with higer score meaning more anxiety.
Cut-points are as follows: 0-4: Minimal anxiety, 5-9: Mild anxiety, 10-14: Moderate anxiety, and 15-21: Severe anxiety.
A score of 10 or greater is often used as a clinical cut-off point.
|
GAD-7 was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
|
|
The reduced Horne & Östberg Morningness-Eveningness Questionnaire (rMEQ)
Lasso di tempo: rMEQ was administered at baseline (day 1).
|
The reduced Horne & Östberg Morningness-Eveningness Questionnaire (rMEQ) is a self-report questionnaire is one of the most widely used questionnaire to measure chronotype.
The rMEQ consists of 5 questions that assess an individual's preference for morning or evening activities.
Based on results from the scoring, individuals can be categorized as: Morning Types: Prefer morning activities; Evening Types: Prefer evening activities or Intermediate Types: Have no strong preference.
|
rMEQ was administered at baseline (day 1).
|
|
The Epworth Sleepiness Scale (ESS)
Lasso di tempo: ESS was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
|
The Epworth Sleepiness Scale (ESS) is widely used in sleep research and clinical settings and consists of 8 questions (each with 4 answering possibilities) about sleepiness.
measure a person's likelihood of dozing off during various daily activities.
ESS provides a score ranging from 0 to 24, with higher scores indicating excessive daytime sleepiness.
In general ESS scores can be interpreted as follows: 0-5 Lower Normal Daytime Sleepiness; 6-10 Higher Normal Daytime Sleepiness; 11-12 Mild Excessive Daytime Sleepiness; 13-15 Moderate Excessive Daytime Sleepiness; and 16-24 Severe Excessive Daytime Sleepiness.
|
ESS was administered at baseline (day 1), FU1 (day 11) and FU2 (day 21).
|
|
Objective measures of cognitive performance: Operation Span (Ospan)
Lasso di tempo: Ospan was administered at baseline (day 1) and FU2 (day 21).
|
Three neuropsychological tests were used to measure cognitive performance: Operation Span (Ospan) is a cognitive task designed to measure working memory capacity by requiring participants to remember sequences of letters while simultaneously solving simple math problems.
This dual-task approach assesses how well individuals can manage their memory resources under distraction.
|
Ospan was administered at baseline (day 1) and FU2 (day 21).
|
|
Objective measures of cognitive performance: Digit span forward
Lasso di tempo: Digit span forward was administered at baseline (day 1) and FU2 (day 21).
|
Three neuropsychological tests were used to measure cognitive performance: Digit span forward is a cognitive task where a person listens to a sequence of numbers and then repeats them back in the same order.
This task primarily measures short-term auditory memory and is commonly used in psychological assessments to evaluate working memory capacity.
|
Digit span forward was administered at baseline (day 1) and FU2 (day 21).
|
|
Objective measures of cognitive performance: Digit span backward
Lasso di tempo: Digit span backward was administered at baseline (day 1) and FU2 (day 21).
|
Three neuropsychological tests were used to measure cognitive performance: Digit span backward is a cognitive task that measures short-term memory by requiring participants to recall a sequence of numbers in reverse order.
This task is more challenging than recalling the numbers in the original order, as it involves both storage and manipulation of the information.
|
Digit span backward was administered at baseline (day 1) and FU2 (day 21).
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Birna Baldursdottir, PhD, Reykjavík University, Iceland
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
- Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
- Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi: 10.1093/sleep/14.6.540.
- Pallesen S, Bjorvatn B, Nordhus IH, Sivertsen B, Hjornevik M, Morin CM. A new scale for measuring insomnia: the Bergen Insomnia Scale. Percept Mot Skills. 2008 Dec;107(3):691-706. doi: 10.2466/pms.107.3.691-706.
- Radloff, L. S. (1977). The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Applied Psychological Measurement, 1(3), 385-401. doi:10.1177/014662167700100306
- Danielsson K, Sakarya A, Jansson-Frojmark M. The reduced Morningness-Eveningness Questionnaire: Psychometric properties and related factors in a young Swedish population. Chronobiol Int. 2019 Apr;36(4):530-540. doi: 10.1080/07420528.2018.1564322. Epub 2019 Jan 7.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
6 marzo 2019
Completamento primario (Effettivo)
8 aprile 2019
Completamento dello studio (Effettivo)
8 aprile 2019
Date di iscrizione allo studio
Primo inviato
29 maggio 2026
Primo inviato che soddisfa i criteri di controllo qualità
15 giugno 2026
Primo Inserito (Effettivo)
22 giugno 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
22 giugno 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
15 giugno 2026
Ultimo verificato
1 giugno 2026
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- VSN-19054
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
SÌ
Descrizione del piano IPD
IPD will be shared upon reasoned requests.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Light Glasses (Experimental)
-
University of Alabama at BirminghamReclutamentoSonno | Disturbo da uso di oppioidi | Ritmi circadiani | Ricerca fMRIStati Uniti
-
American Medical SystemsCompletatoIperplasia prostatica benignaStati Uniti
-
The Miriam HospitalNational Institutes of Health (NIH); National Center for Complementary and Integrative...CompletatoPrevenzione secondaria della malattia coronaricaStati Uniti
-
Icahn School of Medicine at Mount SinaiNational Institute on Aging (NIA)CompletatoMalattia di Alzheimer | Compromissione cognitiva lieveStati Uniti
-
University of BurgundyCompletato
-
Zealand University HospitalUniversity of Copenhagen; Technical University of Denmark; OptoCeuticsCompletatoMalattia di AlzheimerDanimarca
-
Cambridge University Hospitals NHS Foundation TrustCytosystems LtdSconosciutoCancro alla vescica
-
Massachusetts General HospitalAmerican Cancer Society, Inc.Terminato
-
D'Or Institute for Research and EducationTERGOS PESQUISA E ENSINO S.ANon ancora reclutamentoOsteoartrite | GonartrosiBrasile
-
New York Institute of TechnologyCompletatoMorbo di ParkinsonStati Uniti